These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 19426676)

  • 1. Identification of transmembrane domain 6 & 7 residues that contribute to the binding pocket of the urotensin II receptor.
    Holleran BJ; Domazet I; Beaulieu ME; Yan LP; Guillemette G; Lavigne P; Escher E; Leduc R
    Biochem Pharmacol; 2009 Apr; 77(8):1374-82. PubMed ID: 19426676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of transmembrane domain 3, 4 & 5 residues that contribute to the formation of the ligand-binding pocket of the urotensin-II receptor.
    Sainsily X; Cabana J; Boulais PE; Holleran BJ; Escher E; Lavigne P; Leduc R
    Biochem Pharmacol; 2013 Dec; 86(11):1584-93. PubMed ID: 24084430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of the angiotensin II type 1 receptor leads to movement of the sixth transmembrane domain: analysis by the substituted cysteine accessibility method.
    Martin SS; Holleran BJ; Escher E; Guillemette G; Leduc R
    Mol Pharmacol; 2007 Jul; 72(1):182-90. PubMed ID: 17446269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of transmembrane domain 1 & 2 residues that contribute to the formation of the ligand-binding pocket of the urotensin-II receptor.
    Sainsily X; Cabana J; Holleran BJ; Escher E; Lavigne P; Leduc R
    Biochem Pharmacol; 2014 Nov; 92(2):280-8. PubMed ID: 25175740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Photolabelling the urotensin II receptor reveals distinct agonist- and partial-agonist-binding sites.
    Holleran BJ; Beaulieu ME; Proulx CD; Lavigne P; Escher E; Leduc R
    Biochem J; 2007 Feb; 402(1):51-61. PubMed ID: 17064254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis by substituted cysteine scanning mutagenesis of the fourth transmembrane domain of the CXCR4 receptor in its inactive and active state.
    Boulais PE; Escher E; Leduc R
    Biochem Pharmacol; 2013 Feb; 85(4):541-50. PubMed ID: 23219524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selected cysteine residues in transmembrane domains of mu-opioid receptor are critical for effects of sulfhydryl reagents.
    Deng HB; Guang W; Wang JB
    J Pharmacol Exp Ther; 2000 Apr; 293(1):113-20. PubMed ID: 10734160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Photolabelling the rat urotensin II/GPR14 receptor identifies a ligand-binding site in the fourth transmembrane domain.
    Boucard AA; Sauvé SS; Guillemette G; Escher E; Leduc R
    Biochem J; 2003 Mar; 370(Pt 3):829-38. PubMed ID: 12495432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biological properties and functional determinants of the urotensin II receptor.
    Proulx CD; Holleran BJ; Lavigne P; Escher E; Guillemette G; Leduc R
    Peptides; 2008 May; 29(5):691-9. PubMed ID: 18155322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of the third transmembrane domain of the human type 1 angiotensin II receptor by cysteine scanning mutagenesis.
    Martin SS; Boucard AA; Clément M; Escher E; Leduc R; Guillemette G
    J Biol Chem; 2004 Dec; 279(49):51415-23. PubMed ID: 15452107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The conserved cysteine 7.38 residue is differentially accessible in the binding-site crevices of the mu, delta, and kappa opioid receptors.
    Xu W; Chen C; Huang P; Li J; de Riel JK; Javitch JA; Liu-Chen LY
    Biochemistry; 2000 Nov; 39(45):13904-15. PubMed ID: 11076532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Constitutive activation of the angiotensin II type 1 receptor alters the spatial proximity of transmembrane 7 to the ligand-binding pocket.
    Boucard AA; Roy M; Beaulieu ME; Lavigne P; Escher E; Guillemette G; Leduc R
    J Biol Chem; 2003 Sep; 278(38):36628-36. PubMed ID: 12842881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of transmembrane domains 1 and 4 of the human angiotensin II AT1 receptor by cysteine-scanning mutagenesis.
    Yan L; Holleran BJ; Lavigne P; Escher E; Guillemette G; Leduc R
    J Biol Chem; 2010 Jan; 285(4):2284-93. PubMed ID: 19940150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cysteine-scanning mutagenesis and thiol modification of the Rickettsia prowazekii ATP/ADP translocase: evidence that transmembrane regions I and II, but not III, are structural components of the aqueous translocation channel.
    Alexeyev MF; Roberts RA; Daugherty RM; Audia JP; Winkler HH
    Biochemistry; 2004 Jun; 43(22):6995-7002. PubMed ID: 15170337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The fifth transmembrane domain of angiotensin II Type 1 receptor participates in the formation of the ligand-binding pocket and undergoes a counterclockwise rotation upon receptor activation.
    Domazet I; Martin SS; Holleran BJ; Morin ME; Lacasse P; Lavigne P; Escher E; Leduc R; Guillemette G
    J Biol Chem; 2009 Nov; 284(46):31953-61. PubMed ID: 19773549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The second transmembrane domain of the human type 1 angiotensin II receptor participates in the formation of the ligand binding pocket and undergoes integral pivoting movement during the process of receptor activation.
    Domazet I; Holleran BJ; Martin SS; Lavigne P; Leduc R; Escher E; Guillemette G
    J Biol Chem; 2009 May; 284(18):11922-9. PubMed ID: 19276075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Solution structure of urotensin-II receptor extracellular loop III and characterization of its interaction with urotensin-II.
    Boivin S; Ségalas-Milazzo I; Guilhaudis L; Oulyadi H; Fournier A; Davoust D
    Peptides; 2008 May; 29(5):700-10. PubMed ID: 18423797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Electrostatic and aromatic microdomains within the binding-site crevice of the D2 receptor: contributions of the second membrane-spanning segment.
    Javitch JA; Ballesteros JA; Chen J; Chiappa V; Simpson MM
    Biochemistry; 1999 Jun; 38(25):7961-8. PubMed ID: 10387039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ligand-supported purification of the urotensin-II receptor.
    Du AT; Onan D; Dinh DT; Lew MJ; Ziogas J; Aguilar MI; Pattenden LK; Thomas WG
    Mol Pharmacol; 2010 Oct; 78(4):639-47. PubMed ID: 20647393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MTSEA prevents ligand binding to the human melanocortin-4 receptor by modification of cysteine 130 in transmembrane helix 3.
    Cox A; Donnelly D; Kaur M; Cheetham SC; Cockcroft VB; Findlay JB
    FEBS Lett; 2005 Jan; 579(1):285-91. PubMed ID: 15620728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.